Rein Therapeutics (RNTX) EBITDA (2016 - 2025)
Rein Therapeutics (RNTX) EBITDA from Jun 30, 2016 to Dec 31, 2025. The TTM Rein Therapeutics (RNTX) EBITDA is -$51M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Rein Therapeutics (RNTX) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -22.17% |
| 3 Years TTM | +22.59% |
| 5 Years TTM | +20.02% |
| All Time TTM | +16.61% |
Annual EBITDA change of Rein Therapeutics (RNTX)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$51M | -22.17% |
| 2024 | -$65M | +302.54% |
| 2023 | -$16M | -41.19% |
| 2022 | -$27M | +3.78% |
| 2021 | -$26M | +30.25% |
| 2020 | -$20M | -31.78% |
| 2019 | -$30M | -5.93% |
| 2018 | -$32M | +38.46% |
| 2017 | -$23M | +27.54% |
| 2016 | -$18M | +42.72% |
| 2015 | -$13M | N/A |
Comparison Rein Therapeutics (RNTX) five years EBITDA CAGR with competitors
Rein Therapeutics (RNTX) five years EBITDA CAGR is 20.02%.